MAP Pharmaceuticals, Inc. (MAPP) Tops Q2 EPS by 10c
MAPP Hot Sheet
EPS Growth %: 0.0%Financial Fact:
Total operating expenses: 18.87M
Today's EPS Names:
TARO, BRLI, TLB, More
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q2 loss of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $2.55 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- Signet Jewelers (SIG) Tops Q1 EPS by 5c; Guides Q2 Below the Street
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
